# US 2008/0188399 A1 · Drug-Polymer Conjugates Coupled to a Peptidic Carrier

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188399 A1
- Document ID: US20080188399A1
- Status: Published application
- Kind: A1
- Application number: 11/816,317
- Filed: 2006-02-16
- Published: 2008-08-07
- Earliest claimed: 2005-02-16
- Assignees: Ruthers, The State University of New Jersey
- Inventors: Patrick J. Sinko; Stanley Stein; Simi Gunaseelan; Shahriar Pooyan; Li Wan; Xiaoping Zhang
- Web page: https://patentgrep.com/patent/US20080188399A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Monodisperse macromolecular conjugate compositions of a peptidic carrier irreversibly or reversibly conjugated with one or more effectors and one or more therapeutic agents, wherein at least one effector or therapeutic agent is attached to a pendant reactive group on said peptidic carrier via a water-soluble polymer. Monodispersity is obtained through the use of orthogonal and separate conjugation reactions.

## Claims

### Claim 1

A monodisperse macromolecular conjugate composition for in-vivo delivery of a therapeutic agent comprising a peptidic carrier reversibly or irreversibly conjugated with: (a) one or more effectors and (b) one or more therapeutic agents, wherein said peptidic carrier comprises at least two different orthogonal pendant reactive groups each for specific attachment of a predetermined effector or therapeutic agent and at least one effector or therapeutic agent is attached to at least one of said pendant reactive groups on said peptidic carrier via a water-soluble polymer.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said peptidic carrier is selected from the group consisting of a peptide, a peptide mimetic, a pseudopeptide, and a peptide-related compound.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said peptidic carrier comprises 1 to 50 amino acid subunits, amino acid-like subunits, or a combination thereof.

### Claim 4 (depends on 3)

The composition of claim 3, wherein said peptidic carrier comprises 2 to 20 amino acid subunits, amino acid-like subunits, or a combination thereof.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said peptidic carrier comprises 3 to 8 amino acid subunits, amino acid-like subunits, or a combination thereof.

### Claim 6 (depends on 1)

The composition of claim 1, wherein each pendant reactive group is independently selected from the group consisting of a primary amine, a carboxylic acid, an alcohol, a phenol, a thiol, a hydrazide, a hydrazone, a ketone, an oxime, and an aldehyde.

### Claim 7 (depends on 1)

The composition of claim 1, wherein at least one therapeutic agent or effector is attached by reversible bonds to the peptidic carrier or to a water soluble polymer conjugated to said peptidic carrier.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said reversible bond is a disulfide or ester bond.

### Claim 9 (depends on 6)

The composition of claim 6, wherein said peptidic carrier comprises one or more pendant groups formed thereon independently selected from the group consisting of a thiol, a primary amine, a carboxylic acid, an alcohol, and a phenol and said effector or therapeutic agent is conjugated thereto by means of a group reactive therewith on said effector or therapeutic agent.

### Claim 10 (depends on 6)

The composition of claim 6, wherein said peptidic carrier comprises one or more pendant groups formed thereon independently selected from the group consisting of a thiol, a primary amine, a carboxylic acid, an alcohol, and a phenol and said effector or therapeutic agent is conjugated thereto by means of a water-soluble polymer on said effector or therapeutic agent.

### Claim 11 (depends on 1)

The composition of claim 1 comprising 2 to 5 different orthogonal reactive groups attached to the central peptidic core.

### Claim 12 (depends on 6)

The composition of claim 6, wherein there are 1 to 24 copies of each reactive group.

### Claim 13 (depends on 12)

The composition of claim 12, wherein there are 3 to 8 copies of each reactive group.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the peptidic carrier comprises cysteine, lysine, or a combination thereof.

### Claim 15 (depends on 1)

The composition of claim 1, wherein said water-soluble polymer comprises poly(ethylene glycol).

### Claim 16 (depends on 15)

The composition of claim 15, wherein said poly(ethylene glycol) is branched.

### Claim 17 (depends on 15)

The composition of claim 15, wherein said poly(ethylene glycol) has a molecular weight of from 1,000 to 100,000 daltons.

### Claim 18 (depends on 17)

The composition of claim 17, wherein said poly(ethylene glycol) has a molecular weight of from 2,000 to 5,000 daltons.

### Claim 19 (depends on 6)

The composition of claim 6, wherein said reactive group is chemoselective with a reactive group attached to said water soluble polymer prior to conjugation.

### Claim 20 (depends on 6)

The composition of claim 6, wherein said reactive group is chemoselective with a reactive group attached to said effector prior to conjugation.

### Claim 21 (depends on 1)

The composition of claim 1 comprising up to 10 different effectors.

### Claim 22 (depends on 21)

The composition of claim 21 comprising from 1 to 50 copies of each effector.

### Claim 23 (depends on 22)

The composition of claim 22 comprising from 1 to 4 copies of each effector.

### Claim 24 (depends on 1)

The composition of claim 1 comprising up to 10 different therapeutic agents.

### Claim 25 (depends on 24)

The composition of claim 24 comprising from 1 to 50 copies of each therapeutic agent.

### Claim 26 (depends on 25)

The composition of claim 25 comprising from 1 to 4 copies of each therapeutic agent.

### Claim 27 (depends on 1)

The composition of claim 1, wherein said effector is selected from the group consisting of ligands or substrates for receptors, membrane influx or efflux transporters, and enzymes; tissue- and cell-specific targeting groups; permeability enhancers, and modifiers of cell-machinery, cell-signaling or cell-disposition.

### Claim 28 (depends on 1)

The composition of claim 1, wherein said peptidic carrier comprises at least one first reactive group selected from the group consisting of thiols, primary amines, carboxylic acids, alcohols, phenols, hydrazides, hydrazones, ketones, oximes, and aldehydes, to which a first therapeutic agent or first effector is conjugated; and at least one second reactive group orthogonal to said at least one first reactive group and selected from the group consisting of list thiols, primary amines, carboxylic acids, alcohols, phenols, hydrazides, hydrazones, ketones, oximes, and aldehydes to which a second therapeutic agent or second effector is conjugated.

### Claim 29 (depends on 28)

The composition of claim 28, wherein said first therapeutic agent is an anti-retroviral therapeutic agent.

### Claim 30 (depends on 29)

The composition of claim 29, wherein said anti-retroviral therapeutic agent is an AIDS chemotherapeutic agent.

### Claim 31 (depends on 28)

The composition of claim 28, wherein said first effector is a cell surface receptor ligand.

### Claim 32 (depends on 31)

The composition of claim 31, wherein said first effector is fMLF.

### Claim 33 (depends on 31)

The composition of claim 31, wherein said first effector is mannose.

### Claim 34 (depends on 31)

The composition of claim 31, wherein said first effector is folate.

### Claim 35 (depends on 28)

The composition of claim 28, wherein said second therapeutic agent is an antineoplastic therapeutic agent.

### Claim 36 (depends on 35)

The composition of claim 35, wherein said second therapeutic agent is campothecin.

### Claim 37 (depends on 35)

The composition of claim 35, wherein said second therapeutic agent is paclitaxel.

### Claim 38 (depends on 35)

The composition of claim 35, wherein said second therapeutic agent is doxorubicin.

### Claim 39 (depends on 28)

The composition of claim 28, wherein said second effector is a cell penetrating peptide.

### Claim 40 (depends on 39)

The composition of claim 39, wherein said second effector is R.I.Tat9-KC.

### Claim 41

A method for preparing a monodisperse macromolecular conjugate composition for in-vivo delivery of a therapeutic agent, wherein the macromolecular conjugate comprises a peptidic carrier conjugated with one or more effectors and one or more therapeutic agents, wherein the method comprises the steps of:
(a) providing a peptidic carrier comprising first and second orthogonal pendant reactive groups, said first orthogonal pendant reactive group for specific attachment of a predetermined effector and said second orthogonal pendant reactive group for specific attachment of a predetermined therapeutic agent, wherein said peptidic carrier is selected from the group consisting of a peptide, a peptide mimetic, a pseudopeptide, and a peptide-related compound;
(b) attaching said effector to said peptidic carrier by means of a water-soluble polymer such that each copy of an effector is attached to the same reactive groups on each peptidic carrier in the composition; and
(c) attaching said therapeutic agent to said peptidic carrier by means of a water-soluble polymer such that each copy of a therapeutic agent is attached to the same reactive groups on each peptidic carrier in the composition.

### Claim 42

A monodisperse macromolecular conjugate composition comprising a peptidic carrier, wherein said peptidic carrier comprises at least two different orthogonal pendant reactive groups, wherein at least one of said pendant reactive groups on said peptidic carrier is attached to a water-soluble polymer.

### Claim 43 (depends on 42)

The composition of claim 42, wherein said peptidic carrier comprises an amino acid sequence selected from the group consisting of: Cys-beta Ala-Lys; Cys-(beta Ala-Lys)6; Acetyl-Cys-(beta Ala-beta Ala-Lys)2-Amide; Acetyl-Cys-(beta Ala-)beta Ala-Lys)4-Amide; and Cys-(beta Ala-beta Ala-Lys)2.

### Claim 44 (depends on 1)

A method for treating a condition linked to a viral disorder, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1, wherein said therapeutic agent is an anti-infective agent having anti-viral activity and said effector aids the anti-viral action of said therapeutic agent.

### Claim 45 (depends on 1)

A method for treating a condition linked to a microbial disorder, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1, wherein said therapeutic agent is an anti-infective agent having anti-microbial activity and said effector aids the anti-microbial action of said therapeutic agent

### Claim 46 (depends on 1)

A method for treating a condition linked to a viral disorder, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1, wherein said therapeutic agent is an anti-infective agent having anti-viral activity and said effector aids the anti-viral action of said therapeutic agent

### Claim 47 (depends on 1)

A method for treating a condition linked to a hyperproliferative disorder, comprising administering to a patient in need thereof an effective amount of a composition according to claim 1, wherein said therapeutic agent is an anti-neoplastic agent having anti-neoplastic activity and said effector aids the anti-neoplastic action of said therapeutic agent.
